| Juan F Amador, MD | |
|
Cond San Juan # G31, Adoquines, San Juan, PR 00912-3812 | |
| (787) 312-5706 | |
| Not Available |
| Full Name | Juan F Amador |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 15 Years |
| Location | Cond San Juan # G31, San Juan, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811191182 | NPI | - | NPPES |
| 102298180-0001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD436890 (Pennsylvania) | Primary |
| 208D00000X | General Practice | 16413 (Puerto Rico) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hosp Comunitario Buen Samaritano | Aguadilla, PR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Recinto De Ciencias Medicas | 3678469962 | 192 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275556946 PECOS PAC ID: 8527972827 Enrollment ID: O20040605000314 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487677159 PECOS PAC ID: 8527972827 Enrollment ID: O20040721000677 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Aguadilla Medical Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588637789 PECOS PAC ID: 6204816770 Enrollment ID: O20040723001039 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578586244 PECOS PAC ID: 8527972827 Enrollment ID: O20040803000311 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316970833 PECOS PAC ID: 8527972827 Enrollment ID: O20040806000074 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Caribe Physicians Plaza Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215051404 PECOS PAC ID: 0042246712 Enrollment ID: O20050713001119 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Centro Medico Del Turabo Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710107883 PECOS PAC ID: 9335051952 Enrollment ID: O20080212000105 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Insight Management Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891722989 PECOS PAC ID: 8527064062 Enrollment ID: O20100727000180 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Aguada Medical Center Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598057374 PECOS PAC ID: 0840462727 Enrollment ID: O20111019000410 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Recinto De Ciencias Medicas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720166325 PECOS PAC ID: 3678469962 Enrollment ID: O20121018000715 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Recinto De Ciencias Medicas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033272349 PECOS PAC ID: 3678469962 Enrollment ID: O20161129001930 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Dla Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366890311 PECOS PAC ID: 4981986015 Enrollment ID: O20170124002548 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Guaynabo Radiology, Llc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1659858017 PECOS PAC ID: 4082956784 Enrollment ID: O20190429002938 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Oncology & Body Imaging Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699309161 PECOS PAC ID: 1557790110 Enrollment ID: O20200402000048 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Ecoimagenes De Puerto Rico, Corp. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548572555 PECOS PAC ID: 7012280761 Enrollment ID: O20210504000092 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Entity Name | Mmd Breast Imaging Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528776408 PECOS PAC ID: 8628442951 Enrollment ID: O20230328000512 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Juan F Amador, MD G31 Paseo San Juan, Adoquines, San Juan, PR 00926 Ph: (787) 312-5706 | Juan F Amador, MD Cond San Juan # G31, Adoquines, San Juan, PR 00912-3812 Ph: (787) 312-5706 |
News Archive
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis. ICI-induced myocarditis represents a new clinical syndrome because of the novelty and considerable usage of ICIs.
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
Women's hormonal cycles may not only make them more prone to drug addiction but also more affected by triggers that lead to relapse, a new Vanderbilt University study revealed. The findings are especially significant since there are virtually no addiction studies in women that account for these cycles.
Researchers at The Ohio State University Wexner Medical Center are exploring how small changes in the nasal cavity impact airflow and quality of life.
› Verified 1 days ago
Bernardo Jose Marques Diaz, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 310 Lomas Verdes Ave. Suite 208, San Juan, PR 00927 Phone: 787-751-3150 Fax: 787-767-0338 | |
Dr. Roberto F Marchan, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 271 Ave J T Pinero, San Juan, PR 00927 Phone: 787-759-9660 Fax: 787-759-9660 | |
Wilmarie Rivera Hernandez, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 617 Calle Manuel Pavia, San Juan, PR 00909 Phone: 787-625-1446 | |
Dr. Wilma Rodriguez Mojica, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Fernandez Street No. 6 , Third Floor, San Juan, PR 00918 Phone: 787-763-6336 Fax: 787-763-6207 | |
Luis Garcia Paredes, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1462 Calle Prof Augusto Rodriguez, San Juan, PR 00909 Phone: 787-641-1616 | |
Mr. Roberto J Sein, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Ave De Diego 201, Plaza San Fco Ofic #30, San Juan, PR 00927 Phone: 787-751-5587 Fax: 787-753-4631 | |
Dr. Ivonne Marquez Valencia, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 258 Calle San Jorge, San Juan, PR 00912 Phone: 787-727-1000 |